International Conference on Genetics and Molecular Biology
Brussels, Belgium
Biography
Biography: Safaa Aldahlawi
Abstract
Tyrosine Kinase Inhibitors TKIs and other targeted medicines are crucial in the management of CML patients' treatment. However, some patients do continue to experience less favorable and exhibit resistance to therapy. Therefore, the aim of our study is to conduct whole transcriptome sequencing to assess the differential gene expression profile in CML cases according to the patient’s response to TKI-based therapy.Method: Ten samples of human blood taken from CML patients at two different phases (diagnosis stage and relapse stage). All samples were subjected to RNA extraction, and ≤20 µg of RNA were used for NGS sequencing. The DESeq2 R software was used to do the data analysis. Result: A list of 499 genes was found to have significantly differential expression levels in the two study groups in CML cases. 122 genes were discovered to be upregulated in the analysis of gene expression, whereas 377 were found to be downregulated. All deregulated genes showed expression changes greater than |log2FoldChange|>0. There was a highly significant deregulation of NTRK2 (>+5 fold change) and KRT17 (< -5 fold change) expression compared to other genes. The majority of the expressed genes are involved the cell cycle, PI3K-AKT signaling pathway, cellular senescence, oxidative phosphorylation, microRNA in cancer, FOXO, and P53 signaling pathways, as well as other biological processes